钠-葡萄糖耦联转运体2抑制剂治疗糖尿病肾病研究进展  

Advances in the treatment of diabetic nephropathy with sodium-glucose linked transporter-2 inhibitor

作　　者：丛亿蕾 吴腾飞[1] 闵婕 朱逸云 夏诗思 袁玥 杨昕宇 杨华[1] CONG Yilei;WU Tengfei;MIN Jie;ZHU Yiyun;XIA Shisi;YUAN Yue;YANG Xinyu;YANG Hua(Department of Endocrinology,Longhua Hospital Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Department of Nephrology,Longhua Hospital Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院内分泌科,上海200032 [2]上海中医药大学附属龙华医院肾病二科,上海200032

出　　处：《世界临床药物》2023年第9期908-913,共6页World Clinical Drug

基　　金：上海市科学技术委员会项目(20Y21902500);龙华医院第三批人才能力提升计划(RC-2020-01-02)。

摘　　要：钠-葡萄糖耦联转运体2抑制剂(sodium-glucose linked transporter-2 inhibitor,SGLT-2i)是一种目前临床常用的口服降糖药,通过抑制肾小管葡萄糖重吸收、增加尿糖排泄以降低血糖水平,同时增加尿钠排泄,发挥降压、减轻体质量等作用,可多途径治疗糖尿病肾病(diabetic nephropathy,DN)。现简要归纳SGLT-2i在DN发生发展中的作用、机制及疗效等,旨在为临床提供一定参考。Sodium-glucose linked transporter-2 inhibitor(SGLT-2i)is a commonly used oral hypoglycemic agent in clinical practice,which reduces blood glucose by inhibiting renal tubule glucose reabsorption and increasing urinary glucose excretion,while increasing urinary sodium excretion.It plays the role of reducing blood pressure and reducing body mass,and treats diabetic nephropathy(DN)in multiple ways.This article briefly summarized the role,mechanism and clinical efficacy of SGLT-2i in the occurrence and development of DN,aiming to provide some reference for clinical practice.

关 键 词：钠-葡萄糖耦联转运体2抑制剂 糖尿病肾病 作用机制 

分 类 号：R587.1[医药卫生—内分泌] R692.9[医药卫生—内科学]